---
title: 'Vascular Disease Burden, Outcomes, and Benefit with Empagliflozin in Heart
  Failure: Insights from the EMPEROR-Reduced Trial'
date: '2023-08-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37558088/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230810180951&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSION: In patients with HFrEF, the extent of vascular disease is
  associated with the risk for adverse cardiovascular outcomes. Empagliflozin offers
  cardiovascular and renal benefits in HFrEF across the extent of vascular disease,
  but this benefit is attenuated in those with poly-vascular ...'
disable_comments: true
---
CONCLUSION: In patients with HFrEF, the extent of vascular disease is associated with the risk for adverse cardiovascular outcomes. Empagliflozin offers cardiovascular and renal benefits in HFrEF across the extent of vascular disease, but this benefit is attenuated in those with poly-vascular ...